A report published by Deep Knowledge Analytics shows that AI-Friendly chiefs are more likely to help drive their organisation to success.

 

Researchers did a deep dive with 50 pharma and tech corporations and discovered that when CEOs and board members embraced AI, it indicated R&D efficiency and the likelihood of more success in drug discovery.

 
You might also like:
Artificial Intelligence in Healthcare: What is Versus What Will Be

The report identified 100 CEOs and board members who are engaging with AI for their business. According to the report, most are concentrated in Germany, the U.S.A. and Japan and these countries are tipped to become AI research and innovation hubs.

 

“The AI leaders have interdisciplinary skills in both business and technology,” researchers said. “The objective of this report is to establish a benchmark. In the future we expect to observe a correlation between such benchmarking and market and investment prospects with the level of AI commitment serving as an indicator of market capitalisation growth.”

 

Researchers said the deployment of AI meant deeper and more effective business analysis and, ultimately, outperformance in the specified sector.

 

Source: DK Analytics

Image credit: Pixabay

«« The Pitfalls of AI in Healthcare: Bias and Faulty Anonymisation


GDPR-friendly Patient Data: Finland Leads the Way »»



Latest Articles

efficiency, Pharmaceutical, hospital CEOs, Business, AI Research, Board, profitability A report published by Deep Knowledge Analytics shows that AI-Friendly chiefs are more likely to help drive their organisation to success. Researcher...